Media Room
Second Quarter 2025
Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation will be followed by a Q&A session.
15:00 – 16:30 CET (9:00am – 10:30am EDT)
Press releases
June 30, 2025
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
June 25, 2025
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Sustainability Statement 2024 (ESG Report)
XBRL Viewer URD 2024
XBRL Viewer 20F 2024
Registration Document 2024 (in French)